Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Screening and Testing for Homologous Recombination Repair Deficiency (HRD) in Breast Cancer: an Overview of the Current Global Landscape.

Current oncology reports - 1 Aug 2024

Daly Gordon R, Naidoo Sindhuja, Alabdulrahman Mohammad, McGrath Jason, Dowling Gavin P, AlRawashdeh Maen M, Hill Arnold D K, Varešlija Damir, Young Leonie

Abstract excerpt

PURPOSE OF REVIEW: Homologous recombination repair deficiency (HRD) increases breast cancer susceptibility and influences both prophylactic and active management of breast cancer. This review evaluates HRD testing and the therapeutic implications of HRD in a global context. RECENT FINDINGS: Ongoing research efforts have highlighted the importance of HRD beyond BRCA1/2 as a potential therapeutic target in breast...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA1 Protein
Share to BRCA2 Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Breast Neoplasms

Share to Early Detection of Cancer

Share to Genetic Predisposition to Disease

Share to Genetic Testing

Share to High-Throughput Nucleotide Sequencing

Share to Recombinational DNA Repair

Source

Open in PubMed Open full text

Identifiers

PMID: 38822929
DOI: 10.1007/s11912-024-01560-3
PMCID: PMC11300621

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Screening and Testing for Homologous Recombination Repair Deficiency (HRD) in Breast Cancer: an Overview of the Current Global Landscape.PMID 38822929Read ↗

Clinical Utility of Genomic Tests Evaluating Homologous Recombination Repair Deficiency (HRD) for Treatment Decisions in Early and Metastatic Breast CancerSemantic proximity Read ↗

Examining the prevalence of homologous recombination repair defects in ER+ breast cancers.Semantic proximity Read ↗

Homologous recombination deficiency in breast cancer: Implications for risk, cancer development, and therapySemantic proximity Read ↗

Homologous Recombination Deficiency in Ovarian and Breast Cancers: Biomarkers, Diagnosis and TreatmentSemantic proximity Read ↗

Breast Cancer: Epidemiology, Molecular Classification, Diagnostics and Evolving Treatment Paradigms.Semantic proximity Read ↗

Validation of Genomic and Transcriptomic Models of Homologous Recombination Deficiency in a Real-World Pan-Cancer CohortSemantic proximity Read ↗

Homologous Recombination Deficiency Scar: Mutations and Beyond—Implications for Precision OncologySemantic proximity Read ↗

Homologous Recombination Deficiency Across Subtypes of Primary Breast Cancer.Semantic proximity Read ↗

Homologous Recombination Deficiency in Ovarian and Breast Cancers: Biomarkers, Diagnosis, and TreatmentSemantic proximity Read ↗

Homologous recombination deficiency (HRD) testing landscape: clinical applications and technical validation for routine diagnosticsSemantic proximity Read ↗

Genetic Basis of Breast and Ovarian Cancer: Approaches and Lessons Learnt from Three Decades of Inherited Predisposition TestingSemantic proximity Read ↗

Tumor suppressor heterozygosity and homologous recombination deficiency mediate resistance to front-line therapy in breast cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.